Welcome to our dedicated page for Starling Oncology SEC filings (Ticker: DFPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Starling Oncology's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Starling Oncology's regulatory disclosures and financial reporting.
The Oncology Institute, Inc. entered a new $75 million term loan with OrbiMed Opportunities and drew it in full, maturing in 2031. The loan bears interest at the higher of a one‑month SOFR-based rate or 3.00%, plus 5.75%.
The company used the $75 million, together with about $11 million of cash, to repay in full its $86 million 4% senior secured convertible notes due 2027 held by Deerfield. As part of the repayment, it issued Warrants for 10,025,535 shares at an initial exercise price of $8.567 per share, expiring August 9, 2027. The credit agreement includes covenants such as a minimum trailing twelve‑month net revenue of at least $700 million starting with the month ending December 31, 2027.
Oncology Institute, Inc. ten percent owner Jorey Chernett bought 18,000 shares of Common Stock in an open-market purchase. The shares were acquired on June 23, 2026 at a weighted average price of $5.02 per share, in trades ranging from $5.02 to $5.04. After this transaction, Chernett directly owns 10,615,858 shares of Oncology Institute common stock.
The Oncology Institute, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 17, 2026. Stockholders representing 75,242,437 shares of common stock, or 75.26% of the 99,982,933 shares outstanding as of the April 24, 2026 record date, were present or represented by proxy.
All eight director nominees were elected under a plurality vote standard, each receiving over 23 million votes in favor. Stockholders also ratified the appointment of BDO USA, P.C. as independent registered public accounting firm for the fiscal year ending December 31, 2026.
On a non-binding advisory basis, stockholders approved the compensation of the company’s named executive officers and indicated a preference for holding future advisory votes on executive pay every year. The company decided it will continue to hold say-on-pay votes annually until the next required frequency vote.
Morgan Stanley Smith Barney LLC submitted a Form 144 reporting the proposed sale of 23,451 shares of Common Stock on 06/08/2026 related to an exercise of stock options. The filing lists prior sales by Yale Podnos on 05/21/2026, 03/27/2026, and 03/17/2026 with specified share counts and cash amounts.
Chernett Jorey, a ten percent owner of Oncology Institute, Inc., reported an open-market purchase of 12,000 shares of Common Stock on June 4, 2026 at $4.75 per share. Following this transaction, Jorey directly holds 10,579,858 shares of Oncology Institute common stock.
Oncology Institute, Inc. Chief Medical Officer Yale Podnos reported an administrative share transaction involving 1,805 shares of common stock at $4.47 per share. According to a footnote, the issuer executed this sale to cover tax liabilities from the vesting of a restricted stock unit award granted on May 21, 2024. Following this transaction, Podnos directly holds 282,978 shares of common stock, indicating that the event represents a small, routine adjustment related to equity compensation rather than a discretionary market trade.
Oncology Institute, Inc. Chief Executive Officer Daniel Virnich reported an administrative equity transaction involving 23,058 shares of common stock. According to the footnote, the issuer executed a sale of these shares to cover tax liabilities arising from the vesting of a restricted stock unit (RSU) award made on May 21, 2024.
Following this tax-related transaction, Virnich directly holds 2,337,166 shares of common stock. The filing does not show any open-market buying or selling by him, but rather a routine step connected to equity compensation and associated taxes.
Oncology Institute, Inc.’s Chief Financial Officer Robert Ross reported a small administrative share transaction. The issuer sold 1,604 shares of common stock at $4.47 per share to cover tax liabilities from the vesting of an RSU award granted on May 21, 2024. After this tax-related sale, Ross directly holds 414,801 shares of common stock, indicating his overall ownership position remains largely unchanged.
The Oncology Institute, Inc. reported a material cybersecurity incident linked to a software service provider it uses. On May 20, 2026, a third-party administrator informed the company that the vendor had detected unauthorized access to certain company information systems, including systems affecting patient data.
The vendor has established a patient portal to share information and handle inquiries. The company states its technology security and continuity plan allowed operations to continue in all material respects after detection. It plans to work with the vendor to offer credit monitoring and protection to impacted patients and is reserving rights regarding potential claims against third parties.
The company’s investigation is ongoing, but as of this filing it believes the incident has not had a material impact on its operations, financial systems, financial condition, or quality of care, while it continues to evaluate any other material effects.
Oncology Institute, Inc. major shareholder Jorey Chernett reported open‑market purchases of the company’s Common Stock. He bought 5,000 shares on May 19, 2026 at $4.05 per share and 33,500 shares on May 20, 2026 at a weighted average price of $4.07 per share.
Following these transactions, Chernett directly owns 10,567,858 shares of Oncology Institute Common Stock, reflecting additional accumulation by a ten percent owner.